Tetracycline
| Evidence Level: L2 | Predicted Indications: 4 |
Table of Contents
Tetracycline: From Bacterial Infections to Chronic Rhinosinusitis
One-Sentence Summary
Tetracycline is a broad-spectrum bacteriostatic antibiotic historically used to treat bacterial infections, including those caused by atypical pathogens such as Chlamydia. The TxGNN model predicts it may also be effective, via a non-antibiotic anti-inflammatory mechanism, for Chronic Rhinosinusitis (with Nasal Polyps), with 4 clinical trials and 20 publications currently supporting this direction — most of the direct clinical evidence, however, comes from doxycycline, a related tetracycline-class drug, rather than tetracycline itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (broad-spectrum antibacterial; specific TFDA/MHRA-approved indication text not available in this Evidence Pack) |
| Predicted New Indication | Chronic Rhinosinusitis (with Nasal Polyps) |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Other TxGNN-Predicted Indications (Lower Evidence)
This Evidence Pack is a multi-indication candidate. Three additional indications were flagged by TxGNN but carry substantially weaker evidence and are not recommended for further action at this time:
| Predicted Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|
| Chronic ethmoidal sinusitis | 99.15% | L4 | Hold |
| Punctate epithelial keratoconjunctivitis | 99.58% | L5 | Hold |
| Paranasal sinus neoplasm | 99.10% | L5 | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data specific to tetracycline is not available in this Evidence Pack (flagged as a High-severity data gap). Based on known pharmacology, tetracycline is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial 30S ribosomal protein synthesis and has activity against atypical organisms such as Chlamydia. Beyond its antibacterial action, tetracycline-class drugs also possess well-characterised non-antibiotic, anti-inflammatory properties: inhibition of matrix metalloproteinases (particularly MMP-9), reduction of pro-inflammatory cytokine production, and suppression of neutrophil/eosinophil activity.
This secondary mechanism is the pharmacological basis for using tetracycline-class antibiotics — most commonly doxycycline — as adjunctive therapy in chronic rhinosinusitis with nasal polyps (CRSwNP). In CRSwNP, elevated MMP-9 and eosinophilic inflammation drive poor wound healing and high polyp recurrence after surgery; sub-antimicrobial-dose tetracyclines are hypothesised to dampen this inflammatory cascade independently of their antibacterial effect.
Importantly, the great majority of the clinical trial and literature evidence summarised below investigates doxycycline, not tetracycline itself. The extrapolation to tetracycline should therefore be treated as a class-effect inference rather than drug-specific evidence. Tetracycline and doxycycline differ in dosing regimens and in some safety characteristics (e.g. photosensitivity, hepatotoxicity risk, tooth discolouration), so this difference needs to be explicitly considered before any repurposing decision.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05157412 | Phase 3 | Completed | 60 | Evaluated doxycycline as an adjunct to systemic steroids in chronic rhinosinusitis with nasal polyps; the highest-quality completed trial identified for this indication. |
| NCT01825408 | Phase 4 | Completed | 40 | Randomised comparison of 3 vs 6 weeks of antibiotic therapy as part of maximal medical therapy for chronic rhinosinusitis. |
| NCT01198912 | Phase 2 | Completed | 33 | Double-blind, placebo-controlled trial of long-term low-dose oral doxycycline on wound healing quality after endoscopic sinus surgery. |
| NCT02569437 | Phase 2 | Terminated | 49 | Assessed doxycycline combined with oral steroids to reduce symptoms and avoid surgery in moderate-to-severe CRSwNP; trial was terminated early, limiting reliability. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36740870 | 2023 | RCT | American Journal of Rhinology & Allergy | Randomised controlled trial showing doxycycline improved quality of life and anosmia in CRSwNP. |
| 32692788 | 2020 | RCT (double-blind, placebo-controlled) | Rhinology | Clinical outcomes of antibiotic and other medical therapies in CRS were independent of microbiome shifts. |
| 27113482 | 2016 | Systematic Review (Cochrane) | Cochrane Database of Systematic Reviews | Cochrane review of systemic and topical antibiotics as a medical management option for chronic rhinosinusitis. |
| 35919933 | 2023 | Meta-analysis/Systematic Review | Journal of Laryngology & Otology | Systematic review and meta-analysis evaluating the role of doxycycline in chronic rhinosinusitis management. |
| 38512383 | 2024 | Systematic Review/Meta-analysis | European Archives of Oto-Rhino-Laryngology | Compared doxycycline with conventional treatment in refractory CRSwNP. |
| 39937440 | 2025 | Review | Current Opinion in Allergy and Clinical Immunology | Reviews the mechanisms and appropriate patient selection for doxycycline therapy in CRS, including its role alongside newer biologics. |
| 32278453 | 2020 | Review | Immunology and Allergy Clinics of North America | Describes the immunomodulatory (MMP-inhibiting) role of doxycycline as an adjunct antibiotic in recalcitrant CRS. |
| 31126631 | 2019 | Clinical study | American Journal of Otolaryngology | Examined addition of doxycycline to standard anti-inflammatory regimen for CRSwNP outcomes. |
| 28434014 | 2017 | Prospective open-label study | Rhinology | Long-term low-dose oral doxycycline in difficult-to-treat CRSwNP; assessed sustained clinical outcomes. |
| 41186256 | 2026 | Clinical study | International Forum of Allergy & Rhinology | Investigated wound-healing mechanisms after endoscopic sinus surgery and improvement with doxycycline therapy in eosinophilic CRS. |
UK Market Information
Tetracycline currently holds no UK marketing authorisation in this Evidence Pack (market_status: Not marketed, total_licenses: 0). No product licences, brand names, or approved indication text are available for review.
For context, tetracyclines as a class are listed in the BNF under Antibacterials > Tetracyclines; however, this does not constitute an active UK licence for tetracycline itself and should be independently verified against the current BNF and MHRA product database before any regulatory action.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
No structured warnings, contraindications, or drug–drug interaction data were available in this Evidence Pack (flagged as a Blocking data gap: TFDA label warnings/contraindications). This gap currently prevents completion of an initial safety assessment (S1) for this candidate.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 2–4 trials, a Cochrane systematic review, and further systematic reviews/meta-analyses support an anti-inflammatory adjunct role for tetracycline-class antibiotics in chronic rhinosinusitis with nasal polyps. However, nearly all direct clinical evidence concerns doxycycline rather than tetracycline itself, and tetracycline currently holds no UK marketing authorisation, so any progression must be conditional on closing the safety and drug-specificity gaps below. The three other TxGNN-flagged indications (punctate epithelial keratoconjunctivitis, chronic ethmoidal sinusitis, paranasal sinus neoplasm) remain on Hold due to insufficient or non-supportive evidence.
To proceed, the following is needed:
- TFDA/MHRA-equivalent SmPC warnings and contraindications (currently a Blocking data gap; required before initial safety assessment, S1)
- Confirmed mechanism-of-action data specific to tetracycline, to validate the class-effect extrapolation from doxycycline trial evidence
- Assessment of whether tetracycline-specific (rather than doxycycline-only) trial data exist, or whether a dedicated tetracycline trial would be required
- A UK regulatory pathway assessment, given tetracycline’s current unlicensed/not-marketed status
- A safety monitoring plan addressing known tetracycline-class risks (photosensitivity, hepatotoxicity, tooth discolouration) if repurposing is pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.